Location History:
- 7800 Freiburg, DE (1994)
- Freiburg, DE (1992 - 2013)
Company Filing History:
3 out of 3,923 
2 out of 1,678 
1 out of 832,843 Years Active: 1992-2013
Title: **Matthias Kittelmann: Innovator in Organic Compounds**
Introduction
Matthias Kittelmann, an accomplished inventor based in Freiburg, Germany, has made significant contributions to the field of organic chemistry. With a portfolio of six patents, Kittelmann's innovations primarily focus on methods for inhibiting dipeptidyl peptidase-IV (DPP-IV) and their applications in treating various medical conditions.
Latest Patents
Kittelmann's most recent patents pertain to innovative organic compounds designed to inhibit DPP-IV activity. The first patent outlines a method of administering compounds effective for treating mammals with conditions such as non-insulin-dependent diabetes mellitus, arthritis, obesity, and osteoporosis. These compounds are characterized by their versatile structural formulas, including variations where R' and R'' may represent hydrogen, hydroxy, or various alkoxy groups, amongst other substitutions. The second patent also relates to compounds that inhibit DPP-IV activity, which supports their usage as pharmaceuticals in the treatment of conditions mediated by DPP-IV.
Career Highlights
Throughout his career, Matthias Kittelmann has worked with prominent companies in the pharmaceutical and chemical fields, including Novartis AG and Degussa Aktiengesellschaft. His expertise and innovative approach have allowed him to make significant strides in the development of pharmaceutical compounds.
Collaborations
Kittelmann has collaborated with notable professionals in the field, including Maria-Regina Kula and Oreste Ghisalba. These collaborations have facilitated the sharing of knowledge and resources, enhancing the development and efficacy of his inventions.
Conclusion
Matthias Kittelmann's contributions to the field of organic chemistry demonstrate a commitment to innovation and improvement in medical treatments. His patents, focusing on the inhibition of DPP-IV, reflect the important intersection of chemistry and medicine, highlighting his role as a pivotal inventor in this domain.